

Aurora Spine Announces New Pain Care Division

- *Company to offer products into fast growing pain management marketplace* -

CARLSBAD, Calif. — November 30, 2020 -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced it has created a new Pain Care Division focused on the rapidly growing segment of pain care.

Pain management has become more prevalent in recent years as neuro spine and ortho spine surgeons have changed the way they manage patients suffering from chronic back pain issues. Many practices now offer pain management and employ more pain interventionalists than spine surgeons, as there are newer products and services to help treat patients, including Aurora’s ZIP™ and SiLO™. In addition, many pain management physicians are seeking to reduce the use of opioids and increasingly using mechanical devices such as the ZIP™ and SiLO™.

The ZIP™ Screwless Fusion Procedure for the treatment of back pain is a series of patented implants developed by Aurora Spine specifically for the L5-S1 region, including Aurora Spine's minimally invasive interspinous fixation implant designed for stabilization and load sharing in T1-S1 thoracolumbar fusion procedures.

SiLO™ is a single implant Posterior Si-Fusion System and was developed to provide a simple, safe & reproducible method of fusing the Sacroiliac Joint. SiLO™ is the only implant that was designed specifically for posterior sacroiliac joint fusions. The implant design consists of three levels of ridges along its circumferential solid body to increase implant retention and solidity through its unique “Dowel Anchorage Design”. The SiLO implant is shaped for enhanced 360-degree bone incorporation along with dual, vertical side channels.

“We are excited to announce the launch of our new Aurora Spine Pain Care division. The pain management market has experienced sizable growth in recent years and is expected to continue to grow for the foreseeable future,” said Trent Northcutt, President and CEO of Aurora Spine. “The pain care market has been a rapidly growing sector of the spinal health market. Many practices have established pain care within their practices to implement new treatments to treat back pain before sending a patient to surgery. Seeing these shifts in the market, Aurora created new products for the pain care marketplace, including products that can assist pain interventionists when treating patients and avoid or limit the use of opioids. We believe our focus on the pain care market will allow us to leverage several Aurora products into the pain care marketplace and offer patients and doctors more solutions to helping them treat chronic back pain.”

Dr. Vipul Mangal, Director of Implantable Systems at National Spine & Pain Centers in National Harbor, Maryland, stated, “Aurora Pain Care offers modern, minimally invasive treatment of back pain for my

patients. Performing these cases at an outpatient surgery center is the future of minimally invasive spine surgery. I find that the device is easy to implant, and patients have had significant functional improvement in mobility and activities of daily living along with decrease in their pain.”

The global pain management devices market size is expected to reach USD \$14.55 billion by 2026 registering a CAGR of 13.8%. For additional information about Aurora Spine’s Pain Care Division, go to: www.aurorapaincare.com.

About Aurora Spine

Aurora Spine is focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Information" in Aurora Spine's final prospectus (collectively, "forward-looking information"). Forward-looking information in this news release includes information concerning the proposed use and success of the company's products in surgical procedures. Aurora Spine cautions investors of Aurora Spine's securities about important factors that could cause Aurora Spine's actual results to differ materially from those projected in any forward-looking statements included in this news release. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward-looking statements. These statements speak only as of the date of this press release and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances.

Contact:

Aurora Spine Corporation

Trent Northcutt
President and Chief Executive Officer
(760) 424-2004

Chad Clouse
Chief Financial Officer
(760) 424-2004
www.aurora-spine.com

Adam Lowensteiner
LYTHAM PARTNERS, LLC
Phoenix | New York
Telephone: 646-829-9700
arosf@lythampartners.com